Terminalia catappa Extract Palliates Redox Imbalance and Inflammation in Diabetic Rats by Upregulating Nrf-2 Gene

Table 6

Predicted ADMET properties of major T. catappa aqueous leaf extract phytoconstituents and standard diabetic drugs.

	Absorption and distribution						Drug-likeness
	Solubility class	HIA	BBB	Pgp-S	Pgp-I	LV	VV	EV	B	SA	MRTD
9-Oxabicyclo[3.3.1]nonane-2,6-diol	Very	High	No	No	No	0	0	0	0.55	4.31	384
1,2,3-Benzenetriol	Very	High	Yes	No	No	0	0	0	0.55	1	90
Glibenclamide	Poor	Low	No	No	Yes	1	1	0	0.55	3.42	183
Metformin	High	High	No	No	No	0	0	0	0.55	3.02	3000
	Metabolism							Toxicity
	HLM	Cytochrome P450 inhibitor					hERG	DILI	HepG2	MMP	Ames test
		1A2	2C19	2C9	2D6	3A4
9-Oxabicyclo[3.3.1]nonane-2,6-diol	Yes	No	No	No	No	No	No	No	No	No	No
1,2,3-Benzenetriol	Yes	No	No	No	No	Yes	No	No	No	Yes	No
Glibenclamide	No	No	Yes	Yes	No	Yes	No	Yes	No	No	No
Metformin	Yes	No	No	No	No	No	No	No	No	No	No

mg/day, HIA: human intestinal absorption, BBB: blood-brain barrier permeation, Pgp-S: P-glycoprotein substrate, Pgp-I: P-glycoprotein inhibitor, LV: Lipinski violation, VV: Veber violation, EV: Egan violation, B: bioavailability, SA: synthetic accessibility, MRTD: maximum recommended therapeutic dose, HLM: human liver microsomal stability, hERG: human ether-à-go-go-related gene, DILI: drug-induced liver injury, HepG2: HepG2 cytotoxicity, MMP: mitochondrial membrane potential.